Sudan Loganathan
Stock Analyst at Stephens & Co.
(3.67)
# 790
Out of 5,124 analysts
45
Total ratings
55.26%
Success rate
7.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Initiates: Overweight | $95 | $77.51 | +22.56% | 1 | Dec 17, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $65 → $110 | $72.41 | +51.91% | 3 | Dec 11, 2025 | |
| CADL Candel Therapeutics | Reiterates: Overweight | $15 | $5.30 | +183.02% | 2 | Dec 8, 2025 | |
| PYXS Pyxis Oncology | Maintains: Overweight | $5 → $8 | $1.21 | +561.16% | 2 | Nov 24, 2025 | |
| IMNM Immunome | Maintains: Overweight | $25 → $33 | $19.71 | +67.43% | 3 | Nov 17, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $14 → $15 | $11.17 | +34.29% | 3 | Nov 10, 2025 | |
| DCTH Delcath Systems | Maintains: Overweight | $25 → $18 | $10.26 | +75.44% | 4 | Nov 5, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $35 | $23.02 | +52.04% | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Reiterates: Overweight | $6 | $2.03 | +195.57% | 3 | Sep 22, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $45 | $34.94 | +28.79% | 3 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $17.49 | +71.53% | 4 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $29 → $60 | $42.40 | +41.51% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $33 | $22.80 | +44.74% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $3.56 | +124.72% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $15 | $6.61 | +126.93% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.45 | +244.83% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $9.73 | +927.75% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.59 | +1,157.86% | 1 | May 14, 2024 |
Apogee Therapeutics
Dec 17, 2025
Initiates: Overweight
Price Target: $95
Current: $77.51
Upside: +22.56%
Kymera Therapeutics
Dec 11, 2025
Maintains: Overweight
Price Target: $65 → $110
Current: $72.41
Upside: +51.91%
Candel Therapeutics
Dec 8, 2025
Reiterates: Overweight
Price Target: $15
Current: $5.30
Upside: +183.02%
Pyxis Oncology
Nov 24, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $1.21
Upside: +561.16%
Immunome
Nov 17, 2025
Maintains: Overweight
Price Target: $25 → $33
Current: $19.71
Upside: +67.43%
Arvinas
Nov 10, 2025
Maintains: Overweight
Price Target: $14 → $15
Current: $11.17
Upside: +34.29%
Delcath Systems
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $18
Current: $10.26
Upside: +75.44%
Centessa Pharmaceuticals
Oct 28, 2025
Initiates: Overweight
Price Target: $35
Current: $23.02
Upside: +52.04%
C4 Therapeutics
Sep 22, 2025
Reiterates: Overweight
Price Target: $6
Current: $2.03
Upside: +195.57%
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: $45
Current: $34.94
Upside: +28.79%
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $17.49
Upside: +71.53%
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $42.40
Upside: +41.51%
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $22.80
Upside: +44.74%
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $3.56
Upside: +124.72%
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $6.61
Upside: +126.93%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.45
Upside: +244.83%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $9.73
Upside: +927.75%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $1.59
Upside: +1,157.86%